Xoma Corp. (NASDAQ:XOMA)‘s stock had its “market perform” rating reaffirmed by equities researchers at Cowen and Company in a note issued to investors on Thursday.

Other equities analysts also recently issued research reports about the company. Zacks Investment Research upgraded Xoma Corp. from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a research report on Wednesday, October 26th. Jefferies Group reiterated a “hold” rating on shares of Xoma Corp. in a research report on Friday, August 5th. Finally, Wedbush reiterated an “outperform” rating and set a $17.00 price target on shares of Xoma Corp. in a research report on Wednesday, October 19th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Xoma Corp. has a consensus rating of “Hold” and an average price target of $8.33.

Analyst Recommendations for Xoma Corp. (NASDAQ:XOMA)

Xoma Corp. (NASDAQ:XOMA) opened at 6.58 on Thursday. The stock’s 50 day moving average price is $3.13 and its 200 day moving average price is $1.26. Xoma Corp. has a 52-week low of $4.70 and a 52-week high of $32.40. The company’s market cap is $39.67 million.

Xoma Corp. (NASDAQ:XOMA) last issued its quarterly earnings results on Wednesday, November 9th. The company reported ($2.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.40) by $0.32. The business had revenue of $0.64 million for the quarter, compared to analysts’ expectations of $1.29 million. The company’s quarterly revenue was down 69.1% compared to the same quarter last year. Analysts expect that Xoma Corp. will post ($9.30) earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in XOMA. Vanguard Group Inc. boosted its stake in Xoma Corp. by 19.6% in the second quarter. Vanguard Group Inc. now owns 5,321,901 shares of the company’s stock valued at $2,934,000 after buying an additional 871,594 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Xoma Corp. during the first quarter valued at approximately $374,000. Paloma Partners Management Co bought a new stake in Xoma Corp. during the second quarter valued at approximately $185,000. Bellevue Group AG bought a new stake in Xoma Corp. during the first quarter valued at approximately $174,000. Finally, Spark Investment Management LLC boosted its stake in Xoma Corp. by 100.9% in the second quarter. Spark Investment Management LLC now owns 203,900 shares of the company’s stock valued at $112,000 after buying an additional 102,400 shares in the last quarter.

About Xoma Corp.

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

5 Day Chart for NASDAQ:XOMA

Receive News & Stock Ratings for Xoma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xoma Corp. and related stocks with our FREE daily email newsletter.